XORTX Therapeutics Inc.
XRTX.V
TSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.85M | 1.78M | 1.93M | 2.29M | 2.32M |
| Depreciation & Amortization | 112.10K | 109.10K | 105.60K | 111.00K | 117.10K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.54M | 2.42M | 2.54M | 2.79M | 2.62M |
| Operating Income | -2.54M | -2.42M | -2.54M | -2.79M | -2.62M |
| Income Before Tax | -2.66M | -1.94M | -1.88M | -993.10K | -3.31M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.66 | -1.94 | -1.88 | -0.99 | -3.31 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.66M | -1.94M | -1.88M | -993.10K | -3.31M |
| EBIT | -2.54M | -2.42M | -2.54M | -2.79M | -2.62M |
| EBITDA | -2.51M | -2.38M | -2.49M | -2.71M | -2.52M |
| EPS Basic | -3.00 | -2.36 | -2.71 | -1.47 | -6.74 |
| Normalized Basic EPS | -1.88 | -1.48 | -1.69 | -0.92 | -4.22 |
| EPS Diluted | -3.02 | -2.38 | -2.72 | -1.48 | -6.75 |
| Normalized Diluted EPS | -1.88 | -1.48 | -1.69 | -0.92 | -4.22 |
| Average Basic Shares Outstanding | 3.79M | 3.13M | 2.74M | 2.56M | 2.30M |
| Average Diluted Shares Outstanding | 3.79M | 3.13M | 2.74M | 2.56M | 2.30M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |